And to think when I treated (not that long ago 2011) I took over 3000 pills in 48 wks, 1 pill a day for 12 weeks is pretty awesome
Updated results of how the Merck pills fared in more difficult to treat patients, such as those who failed to be helped by prior treatments and those with more advanced liver disease.
April 11, 2014
Merck’s Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection
Clinical Findings Support Initiation of C-EDGE Phase 3 Program
http://www.fortmilltimes.com/2014/04/11/3410625/mercks-investigational-chronic.html
HCV GT1 infected, treatment-naïve cirrhotic patients, MK-5172/MK-8742 treated - 97 percent (28/29 and 29/30) for 12 and 18 weeks, and MK-5172/MK-8742 plus RBV - 90 percent (28/31) and 97 percent (30/31) for 12 and 18 weeks, respectively.
HCV GT1 infected prior-null responder patients (with or without cirrhosis), MK-5172/MK-8742 treated - 91 percent (30/33) and 97 percent (29/30) for 12 and 18 weeks, respectively, and MK-5172/MK-8742 plus RBV treated 94 percent (30/32) and 100 percent (32/32) for the 12 and 18 weeks, respectively.
Treatment-naïve, non-cirrhotic patients with HCV/HIV co-infection, MK-5172/MK-8742 treated for 12 weeks - 90 percent (26/29) and MK-5172/MK-8742 plus RBV for 12 weeks 97 percent (28/29).
more info with charts at link above.
______________________________________________________
5 recently announced studies found for: MK-5172 MK-8742 | Phase 3
4 not yet recruiting and 1 recruiting
http://www.clinicaltrials.gov/ct2/results?term=MK-5172+MK-
8742&recr=&rslt=&type=&cond=&intr=&titles=&outc=&spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&phase=2&rcv_s=&rcv_e=&lup_s=&lup_e=
Or do advance search - terms MK-5172 MK-8742 and check Phase 3
Link problem with the fortmilltimes.com one in my prior comment
Replaced with another media link
Merck’s Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection
Clinical Findings Support Initiation of C-EDGE Phase 3 Program
http://www.businesswire.com/news/home/20140410006486/en/Merck%E2%80%99s-Investigational-Chronic-Hepatitis-Combination-Therapy-MK-5172MK-8742#.U0fYw_ldV8E